---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-190491"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:28:10.681989+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio updates Sorrento settlement terms; securities class action filed

## Summary
- Sorrento settlement hearing set for Aug 14, 2023; two scenarios: pay judgments by Aug 31 or release claims and relinquish NANTibody interests.
- If settlement not approved, ImmunityBio will continue pursuing judgment collection; no receivables recorded as of June 30, 2023.
- Securities class action filed June 30, 2023 in S.D. Cal. alleging false statements re FDA complete response letter for Anktiva (N-803).
- Company believes class action is without merit and intends to defend vigorously; cannot estimate potential loss.
- FDA CRL cited deficiencies at third-party contract manufacturers; BLA for N-803 + BCG for bladder cancer not approved.

## SEC filing metadata
- accession: 0001193125-23-190491
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312523190491/0001193125-23-190491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312523190491/d473206d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-190491
- JSON: https://secwatch.observer/filing/0001193125-23-190491.json
- Plain text: https://secwatch.observer/filing/0001193125-23-190491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.